THANK YOU FOR SUBSCRIBING
The novel coronavirus (Covid-19) has made a knock-on effect on the pharma companies on a global scale over the past few months.
Fremont, CA: Although the pharma industry is fighting against Covid-19 with vaccines and drugs, the industry’s work has been impacted heavily, primarily through the disruption of the supply chain. There is a lot of conflict among the readers of Pharmaceutical Technology on how confident they are regarding the pharma supply chain being able to maintain needed supplies of medicines amid the Covid-19 crisis. It results in creating more confusion about the extent to which the pharma companies are struggling to make and distribute medicines due to the pandemic.
Disruption in pharma supply chain
China is the epicenter of the outbreak, and manufacturing and export were forbidden as the factories were shut down to control the spread of the virus. Currently, while China has relaxed some of the restrictions, several other countries have implemented export controls, which have impacted the pharma supply chains.
Subverting clinical trial
Disruption to supply chains and drug shortages has other repercussions’. It not only affects the patients already taking those drugs but also damages clinical research of investigational medicines that depends on similar manufacturing plants. Even drug trials have been disrupted as an aftermath of the global implementation of social distancing, lockdown, and quarantine measures. Few companies have already declared that they are canceling or temporarily stopping clinical trials due to the pandemic.
Analyzing the ClobalData of Covid-19 pandemic, it was found that the manufacturing of 57 types of drugs can be affected by the restrictions imposed on the export and overall production of drugs throughout China. By far, the FDA has identified two drugs that are falling short in supply due to Covid-19; the first was not named, but the second drug is a sedation drug that is used to put patients on ventilation. Moreover, the regulator has identified more 20 drugs that can be vulnerable.
However, the regulators are looking to support the pharma companies in establishing supply chain stability and clinical trial capacity.